Replies to post #198984 on Anavex Life Sciences Corp (AVXL)

[Biostockclub]

Nice find, Lima. Thank you.

Note of interest on this “dot”:

From the Eisai G2D2 Tweet description:

“Seeking to deliver tailor-designed cutting-edge medicines
Our precision chemistry strategy - in the context of insights from human genetics - is uniquely positioned to deliver tailor-designed small molecule, anti-sense oligo-nucleotide, and other solutions for targeted therapeutics.”

Note: Small molecule. A2-73 is a small molecule. Of course, not neglecting: precision chemistry based on presumably data from human genetics (mentioned). Sounds familiar.


From this link:
https://alzres.biomedcentral.com/articles/10.1186/s13195-016-0181-2


“Several monoclonal antibodies for the treatment of Alzheimer’s disease (AD) have been in development over the last decade. BAN2401 is a monoclonal antibody that selectively binds soluble amyloid ß (Aß) protofibrils.”

BAN2401 is a monoclonal antibody (mab - 100% failure rate in AZ), not a small molecule.

What do we think Eisai thinks their realistic! chances of success for BAN2401 are? (That’s their only “bun in the oven”)

Their current ph 3 trial is not enriched with human genetics which have been mined for precise correlations to specific targets.

So, they turn to this initiative and hop on the “precision train”. But, hey, at least they hopped on! Can not criticize them there! Smart move.

More to ponder. Adds interest to the narrative when taken as a whole.

Thank you for the new find.
As always, wait and see...
(We got this.)

Bio

[Jonjones325]

Does this smell like collaboration or competition?

Thanks for taking the lead on this little guy (Anavex) and showing us the way, now let the big boys take over.

I hope not.

Hampel, friend or frenemy?

We better move faster. Once BP money wakes up, they won’t be far behind.

They can move fast and break things.